Showing results (1-10 of 443) with videos related to
Sort By:
Pageof 45
Cancer Medicine|January 10, 2014
PD-1 as a potential target in cancer therapyDavid F McDermott, Michael B AtkinsJournal for Immunotherapy of Cancer|August 27, 2025
How can we increase the value of clinical trials with immunotherapy?Michael B Atkins, David F McdermottSeminars in Oncology|August 27, 2013
Immune therapy for kidney cancer: a second dawn?David F McDermott, Michael B AtkinsCancer Journal (Sudbury, Mass.)|October 7, 2008
Immunotherapy of metastatic renal cell carcinomaDavid F McDermott, Michael B AtkinsExpert Opinion on Biological Therapy|April 23, 2004
Application of IL-2 and other cytokines in renal cancerDavid F McDermott, Michael B AtkinsSeminars in Oncology|October 19, 2006
Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of responseDavid F McDermott, Michael B AtkinsNature Reviews. Urology|February 6, 2020
Checkpoint inhibitor immunotherapy in kidney cancerWenxin Xu, Michael B Atkins, David F McDermottCancer Management and Research|December 29, 2010
Management of metastatic renal cell carcinoma in patients with poor prognosisAndrea Bullock, David F McDermott, Michael B AtkinsClinical Genitourinary Cancer|October 10, 2006
Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trialsDavid F McDermott, Meredith M Regan, Michael B AtkinsJournal of Immunotherapy (Hagerstown, Md. : 1997)|August 23, 2005
Histologic predictors of renal cell carcinoma response to interleukin-2-based therapyMelissa P Upton, Robert A Parker, Amanda Youmans, et al.Pageof 45